Langerhans cell histiocytosis: Treatment failure with imatinib

Archives of Dermatology

Volumn 145, Issue 8, 2009, Pages 949-950

  Wagner, Christina ^a   Mohme, Henrik ^b   Krömer Olbrisch, Tanja ^b   Stadler, Rudolf ^b   Goerdt, Sergij ^b   Kurzen, Hjalmar ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMATINIB; IMIQUIMOD; METHOTREXATE; PROTEIN S 100; PSORALEN; T6 ANTIGEN; THALIDOMIDE; VINBLASTINE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTIGEN ANTIBODY REACTION; BONE LESION; CASE REPORT; DEATH; DEPRESSION; DISEASE COURSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATOMEGALY; HISTIOCYTE; HISTIOCYTOSIS X; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOALBUMINEMIA; IMMUNOHISTOCHEMISTRY; INTERNATIONAL NORMALIZED RATIO; LETTER; MALE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PUVA; SKIN DEFECT;

ADULT; AGED, 80 AND OVER; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SKIN DISEASES; TREATMENT FAILURE; YOUNG ADULT;

EID: 68949088303     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.164     Document Type: Letter

References (5)

1. Götz G, Fichter J. Langerhans' cell histiocytosis in 58 adults. Eur J Med Res. 2004;9(11):510-514.
2. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. N Engl J Med. 2004;351(10):1034-1035.
3. Utikal J, Ugurel S, Kurzen H, et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol. 2007;143(6):736-740.
4. McClain KL. Drug therapy for treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother. 2005;6(14):2435-2441.
5. Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H; DAL-HX Study Group. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol. 2002;39(6):581-585.